The mission of this Shared Resource is to provide histologic and hematopoietic research support services toUCSF Comprehensive Cancer Center (CCC) investigators studying the pathogenesis and treatment of organand hematologic malignancies in mouse models of human cancer. This facility provides services formembers of many of the CCC programs. Histology services include processing, embedding, and histologicsectioning of murine tissues in paraffin and frozen blocks (with re-embedding of tissue as necessary), routinehistochemical staining (hematoxylin and eosin) and other special histochemical stains. The Shared Resourcealso provides expertise in murine hematology. Complete blood counts are provided for investigators,including preparation of blood smears for analysis of white blood cell, red blood cell, and plateletmorphology. In addition, the Shared Resource assists investigators analyzing hematopoietic tissues,including cytologic and histologic preparations of bone marrow, spleen, and lymph nodes. Another serviceprovided by the Shared Resource is access to outside veterinary laboratory testing (e.g. serum chemistryassays). The Shared Resource runs a mouse pathology workshop, provides pathologic consultation, andprovides both training on and access to the equipment utilized for pathologic analyses of mice.The Mouse Pathology Shared Resource was used by laboratory personnel representing 50 differentinvestigators at the CCC, providing a total of 14,051 units of service during the most recent 12 month period.Investigators in many of the CC programs have relied upon the Shared Resource not only for direct services,but also for the training of their personnel. The results of the Mouse Pathology Shared Resource are evidentin the extensive publications that reflect the use of mouse models by the investigators that utilize this service.
| Sannino, Sara; Guerriero, Christopher J; Sabnis, Amit J et al. (2018) Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. J Cell Sci 131: |
| Lam, Christine; Ferguson, Ian D; Mariano, Margarette C et al. (2018) Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica 103:1218-1228 |
| Truillet, Charles; Parker, Matthew F L; Huynh, Loc T et al. (2018) Measuring glucocorticoid receptor expression in vivo with PET. Oncotarget 9:20399-20408 |
| Phillips, Kathryn A; Trosman, Julia R; Deverka, Patricia A et al. (2018) Insurance coverage for genomic tests. Science 360:278-279 |
| Phillips, Kathryn A (2018) Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA 319:2379-2380 |
| Puri, Sapna; Roy, Nilotpal; Russ, Holger A et al. (2018) Replication confers ? cell immaturity. Nat Commun 9:485 |
| An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575 |
| Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3: |
| Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607 |
| An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794 |
Showing the most recent 10 out of 192 publications
